Nearly 11% of women experience severe complications.

A report from the Ethics and Public Policy Center (EPPC) reviewed nearly 866,000 abortions induced by mifepristone – the pill now used in roughly two-thirds of all U.S. abortions.

MORE NEWS: Green Energy Control: Michigan House Votes for Local Say Over Solar and Wind Projects

EPPC says, “This largest-known study of the abortion pill is based on analysis of data from an all- payer insurance claims database that includes 865,727 prescribed mifepristone abortions from 2017 to 2023.”

In the study, they found that a staggering 10.93% of women experienced severe or life-threatening complications such as hemorrhaging, sepsis, or infection within just 45 days.

Compare that to what EPPC describes as a “less than 0.5%” figure slapped on the drug’s FDA label, and you’ve got a 22-times-higher risk than what’s been spoon-fed to the public. It’s a significant concern when a powerful medication is being distributed across the country with about as much oversight as a fast-food menu.

Let’s do the math. The Guttmacher Institute estimates there were over 1 million abortions in 2023, with 63% – about 630,000 – done via pills like mifepristone and misoprostol (often used in conjunction with mifepristone). If 10.93% of those women faced severe complications, that’s nearly 69,000 American women who could possibly be dealing with trauma that the FDA apparently didn’t think was worth reporting on – or might not be aware of.

Over the counter catastrophe? Abortion goes DIY – and so do the ER visits.

The pill’s rise in popularity comes after a series of deregulations, courtesy of the Obama and Biden Democratic pro-abortion administrations – including eliminating in-person doctor visits and greenlighting mail-order abortions with minimal oversight. Now, it’s a do-it-yourself operation complete with telehealth visits, no physical exam, and apparently a prayer that you don’t end up in the ER.

Critics, however, say this “convenience” masks a ticking time bomb.

Lawmakers and others urge FDA to restore safety rules for abortion pill after alarming study.

MORE NEWS: As Communities Struggle With Homeless, Debate in Grand Rapids Starts Over Placement of a Shelter

The EPPC calls for the agency to “immediately reinstate its earlier, stronger patient safety protocols to ensure physician responsibility for women who take mifepristone under their care, as well as mandate full reporting of its side effects.”

The authors of the study go on to say, “The FDA should further investigate the harm mifepristone causes to women and, based on objective safety criteria, reconsider its approval altogether.”